OP0024 Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study

N. Damjanov; M. Tlustochowicz; J. Aelion; A. Dimic; M. Greenwald; A. Diehl; I. Bhattacharya; S. Menon; I. Gourley

doi:10.1136/annrheumdis-2012-eular.1707

OP0024 Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1707 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 60.3-61

Author(s):

N. Damjanov ◽

M. Tlustochowicz ◽

J. Aelion ◽

A. Dimic ◽

M. Greenwald ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)

Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164186.624873 ◽

2009 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)

SAT0145 Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of A Randomized, Double-Blind, Placebo-Controlled Study: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3741 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 717.1-717

Author(s):

T. Takeuchi ◽

C. Thorne ◽

G. Karpouzas ◽

S. Sheng ◽

W. Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Drug Treatment ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Treatment Results ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Get full-text (via PubEx)

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation Research ◽

10.1007/s00011-019-01218-y ◽

2019 ◽

Vol 68 (4) ◽

pp. 261-274 ◽

Cited By ~ 1

Author(s):

David L. Boyle ◽

Samuel E. DePrimo ◽

Cesar Calderon ◽

Dion Chen ◽

Paul J. Dunford ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Mechanism Of Action ◽

Active Rheumatoid Arthritis ◽

Phase 2 ◽

Histamine H4 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

H4 Receptor ◽

Orally Active

Get full-text (via PubEx)

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1708 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 61.1-61 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

M.E. Weinblatt ◽

J.S. Smolen

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Get full-text (via PubEx)

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

Arthritis & Rheumatism ◽

10.1002/art.24567 ◽

2009 ◽

Vol 60 (7) ◽

pp. 1895-1905 ◽

Cited By ~ 373

Author(s):

Joel M. Kremer ◽

Bradley J. Bloom ◽

Ferdinand C. Breedveld ◽

John H. Coombs ◽

Mark P. Fletcher ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

Arthritis & Rheumatism ◽

10.1002/art.34506 ◽

2012 ◽

Vol 64 (5) ◽

pp. 1487-1487 ◽

Cited By ~ 1

Author(s):

Joel M. Kremer ◽

Bradley J. Bloom ◽

Ferdinand C. Breedveld ◽

John H. Coombs ◽

Mark P. Fletcher ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)

Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis - a double blind placebo controlled study

Inflammation Research ◽

10.1007/pl00000240 ◽

2001 ◽

Vol 50 (12) ◽

pp. 598-601 ◽

Cited By ~ 8

Author(s):

H. Valleala ◽

K. Laitinen ◽

L. Pylkkänen ◽

Y.T. Konttinen ◽

C. Friman

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Biochemical Response ◽

Controlled Study ◽

Single Infusion ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Faculty Opinions recommendation of A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717983097.793473289 ◽

2013 ◽

Author(s):

Walter Hasibeder

Keyword(s):

Severe Sepsis ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Get full-text (via PubEx)

The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in People with Major Depression: Protocol for a Phase 2, Double-blind, Placebo-controlled Study (Preprint)

JMIR Research Protocols ◽

10.2196/31439 ◽

2021 ◽

Author(s):

Arthi Chinna Meyyappan ◽

Cassandra Sgarbossa ◽

Gustavo Vazquez ◽

David J. Bond ◽

Daniel J. Müller ◽

...

Keyword(s):

Major Depression ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Microbial Ecosystem ◽

Safety And Efficacy ◽

Double Blind Placebo

Get full-text (via PubEx)